Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Sponsor: Mayo Clinic
Summary
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Official title: Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2025-02-03
Completion Date
2026-12
Last Updated
2025-10-07
Healthy Volunteers
No
Conditions
Interventions
Entresto Pill
Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
Placebo
Patients taking placebo tablets will take 1 tablet orally, twice daily
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States